降钙素原对早期急性呼吸窘迫综合征严重程度及预后的预测价值:一项前瞻性观察研究
该前瞻性观察研究纳入2012年10月至2016年4月江苏大学附属人民医院ICU收治的113例机械通气ARDS患者,最终89例纳入分析(轻度27例、中度34例、重度28例),另设25名健康对照。诊断ARDS后24小时内检测血清PCT与CRP,结果显示ARDS组PCT和CRP均显著高于健康对照,且随病程持续上升。PCT与APACHE II评分相关(r=0.669),与Murray评分弱相关(r=0.294),CRP与Murray评分无关。非存活组(n=38)APACHE II评分和PCT显著高于存活组(n=51),PCT预测28天死亡的AUC为0.793,优于Murray评分(0.606)和CRP(0.561);APACHE II联合PCT的AUC为0.859,高于单用PCT(0.793)或APACHE II(0.781)。PCT>4.35 μg/L者28天累积生存率更低。
要点
- 早期ARDS患者诊断后24小时内血清PCT显著高于健康对照[3.46(1.98,5.56)μg/L vs. 0.02(0.01,0.04)μg/L,P<0.01],且随病程持续上升。
- PCT预测28天死亡的AUC为0.793,优于Murray评分(0.606)和CRP(0.561),均P<0.05。
- APACHE II联合PCT预测28天死亡的AUC为0.859,高于单用PCT(0.793,P=0.048)或单用APACHE II(0.781,P=0.038)。
- PCT>4.35 μg/L预测28天死亡敏感度92.2%、特异度63.2%,阳性似然比2.50、阴性似然比0.12。
- PCT>4.35 μg/L者28天累积生存率低于PCT≤4.35 μg/L者(log-rank检验χ2=5.013,P=0.025)。
适用人群与场景
- 江苏大学附属人民医院ICU收治的机械通气ARDS患者,按柏林定义氧合指数分为轻度、中度、重度。
- 最终分析89例,其中轻度27例、中度34例、重度28例;另设25名健康志愿者为对照。
诊断标准与关键阈值
- 按柏林定义以氧合指数(PaO2/FiO2)将ARDS分为轻度、中度、重度。
- PCT>4.35 μg/L作为预测28天死亡的截断值,敏感度92.2%、特异度63.2%,阳性似然比2.50、阴性似然比0.12。
研究设计与关键结果
- 前瞻性观察研究,最终纳入89例ARDS患者和25名健康对照;ARDS病因以感染(55.1%)和创伤(34.8%)最常见。
- ARDS组CRP和PCT均高于健康对照组[CRP(mg/L):146.32(111.31,168.49)vs. 6.08(4.47,7.89);PCT(μg/L):3.46(1.98,5.56)vs. 0.02(0.01,0.04),均P<0.01],且随ARDS病程持续上升。
- 重度组APACHE II评分和Murray评分显著高于轻度组。
- PCT与APACHE II评分相关(r=0.669,P<0.001),与Murray评分弱正相关(r=0.294,P=0.005);CRP与APACHE II评分相关(r=0.601,P<0.001),与Murray评分无关(r=0.203,P=0.052)。
- 非存活组(n=38)APACHE II评分和PCT显著高于存活组[ n=51;APACHE II评分:26.00(23.00,28.50)vs. 21.00(17.00,25.00);PCT(μg/L):6.38(2.82,9.49)vs. 3.09(1.08,3.57),均P<0.01],但两组Murray评分和CRP水平相似。
- PCT和APACHE II评分预测28天死亡的AUC分别为0.793和0.781,优于Murray评分(0.606)和CRP(0.561),均P<0.05;APACHE II联合PCT的AUC为0.859,高于单用PCT(0.793,P=0.048)或单用APACHE II(0.781,P=0.038)。
- PCT>4.35 μg/L者28天累积生存率低于PCT≤4.35 μg/L者(log-rank检验χ2=5.013,P=0.025)。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在早期ARDS诊断后24小时内检测血清PCT,可辅助评估肺损伤严重程度和28天死亡风险,PCT>4.35 μg/L提示预后较差。
- APACHE II评分联合PCT较单用任一指标对28天死亡有更好的预测价值(AUC 0.859 vs. 0.793和0.781)。
- 作者认为,ARDS患者血清PCT升高似乎与肺损伤严重程度相关,并可能是早期ARDS有用的预后标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the value of procalcitonin (PCT) on predicting the severity and prognosis in patients with early acute respiratory distress syndrome (ARDS).
METHODS: A prospective observation study was conducted. A total of 113 patients with ARDS undergoing mechanical ventilation admitted to intensive care unit (ICU) of Affiliated People's Hospital of Jiangsu University from October 2012 to April 2016 were enrolled. Based on oxygenation index (PaO2/FiO2), the patients were classified into mild, moderate, and severe groups according to Berlin Definition. Twenty-five healthy volunteers were served as controls. Demographics, acute physiology and chronic health evaluation II (APACHE II) score, and Murray lung injury score were recorded. Within 24 hours after diagnosis of ARDS, the serum levels of PCT and C-reactive protein (CRP) were determined by enzyme-linked fluorescence analysis (ELFA) and immune turbidimetric method, respectively. The patients were also divided into survival and non-survival groups according to clinical outcome within 28-day follow-up, and the clinical data were compared between the two groups. Spearman rank correlation was applied to determine the correlation between variables. The predictive value of the parameters on 28-day mortality was evaluated with receiver operating characteristic curve (ROC). Kaplan-Meier survival curve analysis was used to compare different PCT levels of patients with 28-day cumulative survival rate.
RESULTS: After excluding patients who did not meet the inclusion criteria and loss to follow-up, the final 89 patients were enrolled in the analysis. Among 89 ARDS patients analyzed, 27 of them were mild, 34 moderate, and 28 severe ARDS. No significant differences were found in age and gender between ARDS and healthy control groups. Infection and trauma were the most common etiology of ARDS (55.1% and 34.8%, respectively). Compared with healthy control group, both CRP and PCT in serum of ARDS group were higher [CRP (mg/L): 146.32 (111.31, 168.49) vs. 6.08 (4.47, 7.89), PCT (μg/L): 3.46 (1.98, 5.56) vs. 0.02 (0.01, 0.04), both P < 0.01], and the two showed sustained upward trends with the ARDS course of disease. Compared with mild group, severe group had significantly higher APACHE II and Murray scores. Spearman rank correlation analysis showed that both serum PCT and CRP in patients with ARDS was correlated well with APACHE II score (r values were 0.669 and 0.601, respectively, both P < 0.001), while PCT was weakly but positively correlated with Murray score (r = 0.294, P = 0.005), but not the case of CRP (r = 0.203, P = 0.052). APACHE II score and serum PCT in non-survival group (n = 38) were significantly higher than those of the survival group [n = 51; APACHE II score: 26.00 (23.00, 28.50) vs. 21.00 (17.00, 25.00), PCT (μg/L): 6.38 (2.82, 9.49) vs. 3.09 (1.08, 3.57), both P < 0.01], but Murray score and CRP level were similar between survivors and non-survivors. The areas under ROC curve (AUC) of APACHE II score and PCT for predicting 28-day mortality were 0.781 and 0.793, respectively, which were better than those of AUC of Murray score and CRP (0.606 and 0.561, respectively, all P < 0.05). The AUC of APACHE II score combined with PCT was significantly higher than that of PCT (0.859 vs. 0.793, P = 0.048) or APACHE II score alone (0.859 vs. 0.781, P = 0.038). Using a PCT cut-off value of > 4.35 μg/L for predicting 28-day mortality, the sensitivity and specificity was 92.2% and 63.2%, respectively, and the positive and negative likelihood ratios were 2.50 and 0.12 respectively. Kaplan-Meier survival curve analysis indicated that the patients whose PCT more than 4.35 μg/L, had lower 28-day cummulative survival rate as compared with those with PCT ≤ 4.35 μg/L (log-rank test: χ2 = 5.013, P = 0.025).
CONCLUSIONS: The elevated serum PCT level in patients with ARDS seems to be correlated well with the severity of lung injury, and appears to be a useful prognostic marker of outcome in the early phases of ARDS.
参考来源
- Yu Z, Ji M, Hu X, et al. [Value of procalcitonin on predicting the severity and prognosis in patients with early ARDS: a prospective observation study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28459401. doi:10.3760/cma.j.issn.2095-4352.2017.01.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。